GlassScriptPhysician profile
Kaitlyn E Edgington
NPI 1932675709
$1,698.21
in general payments reported to CMS, 2019-2025
26 companies · $692 in 2025
The $692 reported for 2025 was more than what 77% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $96.09 · 2022: $274 · 2023: $83.26 · 2024: $552 · 2025: $692.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,328.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,327.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $382.65 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $302.96 | 2022-2025 | |
| Pfizer INC. | $177.74 | 2025 | |
| Novo Nordisk INC | $116.01 | 2021-2025 | Ozempic, Rybelsus |
| Amgen INC. | $108.05 | 2025 | Otezla, Repatha, Krystexxa |
| Lilly USA, LLC | $79.01 | 2021-2024 | Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $74.85 | 2022-2025 | Jardiance |
| Phathom Pharmaceuticals, INC. | $49.39 | 2024 | Voquezna |
| Noven Therapeutics, LLC | $36.19 | 2024 | Xelstrym |
| Tris Pharma INC | $35.29 | 2024 | Dyanavel Xr |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $34.08 | 2024 | Xifaxan, Trulance |
| Amneal Pharmaceuticals LLC | $33.47 | 2024 | Unithroid |
| Edwards Lifesciences Corporation | $26.52 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Organon LLC | $26.26 | 2025 | Nexplanon |
| Glaxosmithkline, LLC. | $25.93 | 2022-2023 | Trelegy Ellipta |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Impel Pharmaceuticals INC. | $22.73 | 2022 | |
| Astellas Pharma US INC | $20.64 | 2024 | Veozah |
| Axsome Therapeutics, INC. | $20.50 | 2025 | Symbravo |
| Otsuka America Pharmaceutical, INC. | $20.16 | 2023 | Rexulti |
| Actelion Pharmaceuticals US, INC. | $16.66 | 2025 | Opsumit, Uptravi |
| Janssen Pharmaceuticals, INC | $16.61 | 2021 | |
| Phadia US INC. | $16.02 | 2024 | Immunocap |
| Corcept Therapeutics | $16.01 | 2025 | Korlym |
| Tolmar, INC. | $15.90 | 2025 | Jatenzo |
| Jazz Pharmaceuticals INC. | $12.90 | 2021 | |
| Upsher-Smith Laboratories LLC | $11.68 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kaitlyn Edgington listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.